Latest news
-
-
February 5, 2015
Almac Appoints VP Quality and Regulatory Affairs
-
January 28, 2014
Data Presented Supporting Almac Developed Colon Signature as a Significant Predictor of Risk of Recurrence in Stage II Colon Cancer
-
January 21, 2014
Almac publishes breast cancer chemotherapy response assay in the Journal of the National Cancer Institute
-
November 26, 2013
Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Risk Breast Cancer
-
September 10, 2013
Almac Offering TruSight Tumor Profiling Next-Generation Sequencing Service
-
February 1, 2012
Almac announce launch of Next Generation Sequencing (NGS) Data Analysis Services
-
November 30, 2011
Almac’s Diagnostic Laboratory Receives Accreditation from College of American Pathologists
-
November 8, 2011
Almac publishes Stage II colon cancer recurrence signature in the Journal of Clinical Oncology